Literature DB >> 9106738

Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells.

A E Aplin1, J S Jacobsen, B H Anderton, J M Gallo.   

Abstract

Aberrant control of protein phosphorylation is an important feature in Alzheimer's disease pathology. The action of glycogen synthase kinase-3 beta (GSK-3 beta) on the maturation and phosphorylation of an amyloid precursor protein-reporter construct (APP-REP) was studied in transfected COS-7 cells. Elevation of GSK-3 beta activity by enzyme over-expression resulted in an increase in the level of mature forms of co-expressed APP-REP. This effect was not associated with an increased level of APP-REP phosphorylation at Thr743, an in vitro GSK-3 beta phosphorylation site. These findings suggest that GSK-3 beta activity may indirectly increase cellular maturation of APP, which may subsequently result in altered production of beta-amyloid protein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106738     DOI: 10.1097/00001756-199702100-00012

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

1.  Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.

Authors:  B DaRocha-Souto; M Coma; B G Pérez-Nievas; T C Scotton; M Siao; P Sánchez-Ferrer; T Hashimoto; Z Fan; E Hudry; I Barroeta; L Serenó; M Rodríguez; M B Sánchez; B T Hyman; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

Review 2.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

Review 3.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

4.  Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase.

Authors:  A Mudher; S Chapman; J Richardson; A Asuni; G Gibb; C Pollard; R Killick; T Iqbal; L Raymond; I Varndell; P Sheppard; A Makoff; E Gower; P E Soden; P Lewis; M Murphy; T E Golde; H T Rupniak; B H Anderton; S Lovestone
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

Review 5.  Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better?

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-01       Impact factor: 1.990

Review 6.  Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets.

Authors:  Virginia M-Y Lee; Kurt R Brunden; Michael Hutton; John Q Trojanowski
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 7.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.

Authors:  Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

8.  GSK-3 in Neurodegenerative Diseases.

Authors:  Peng Lei; Scott Ayton; Ashley I Bush; Paul A Adlard
Journal:  Int J Alzheimers Dis       Date:  2011-05-04

9.  Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3.

Authors:  Marjelo A Mines; Eleonore Beurel; Richard S Jope
Journal:  Int J Alzheimers Dis       Date:  2011-05-11

10.  The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents.

Authors:  Guy Griebel; Jeanne Stemmelin; Mati Lopez-Grancha; Denis Boulay; Gerald Boquet; Franck Slowinski; Philippe Pichat; Sandra Beeské; Shinji Tanaka; Akiko Mori; Masatake Fujimura; Junichi Eguchi
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.